Crescita Announces Filing of New Medical Device License
News provided by
Share this article
ART-FILLER
® Injectables in Canada
LAVAL, QC, Jan. 21, 2021 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) ( Crescita or the Company ), a commercial dermatology, today announced that Laboratoires FILLMED ( FILLMED ) has submitted a New Medical Device License ( MDL ) application for the ART FILLER
® range of products.
Crescita and FILLMED entered into an agreement in January 2020, granting Crescita the exclusive rights to distribute the ART-FILLER injectables product range and the New Cellular Treatment Factor
® ( NCTF
® ) in Canada. The ART FILLER is an exclusive collection of five hyaluronic acid ( HA )-based fillers. Since it was developed in 2016, healthcare professionals including dermatologists and plastic surgeons outside Canada have used it to create or restore the volumes and contours of the face, to temporarily eliminate superficial-to-deep